PubRank

Scott Metcalfe

Author PubWeight™ 32.44‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 PHARMAC responds on long-acting insulin analogues. N Z Med J 2005 1.53
2 Going against the flow: the impact of PHARMAC not funding COX-2 inhibitors for chronic arthritis. N Z Med J 2005 1.53
3 Do pharmaceutical score cards give us the answers we seek? N Z Med J 2011 1.43
4 PHARMAC and tobacco control in New Zealand: two licensed funded options are already available. N Z Med J 2005 1.40
5 Variation in the use of medicines by ethnicity during 2006/07 in New Zealand: a preliminary analysis. N Z Med J 2013 1.40
6 PHARMAC's response on temozolomide and funding costly medicines that prolong life shortly. N Z Med J 2005 1.39
7 Climate science, denial and the Declaration of Delhi. N Z Med J 2009 1.39
8 Direct-to-consumer advertising--yes it can compromise patient health. N Z Med J 2003 1.39
9 Terminations of pregnancy associated with isotretinoin use in New Zealand. N Z Med J 2011 1.39
10 PHARMAC responds to Richard Milne on discounting health benefits and costs. N Z Med J 2005 1.36
11 Health and equity impacts of climate change in Aotearoa-New Zealand, and health gains from climate action. N Z Med J 2014 0.99
12 PHARMAC responds to Stewart Mann on dihydropyridine calcium channel antagonists. N Z Med J 2005 0.97
13 Our advice? Get a budget! Healthc Pap 2002 0.94
14 Old letters, new rules. Lancet 2003 0.93
15 National prescribing data for dabigatran. N Z Med J 2012 0.85
16 Response from PHARMAC: difficult choices. N Z Med J 2003 0.84
17 Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Celecoxib's relative gastrointestinal safety is overstated. BMJ 2003 0.81
18 Assessing the value for money of pharmaceuticals in New Zealand--PHARMAC's approach to cost-utility analysis. N Z Med J 2013 0.80
19 Seretide meta-analysis missed important features and overstates any advantages over concurrent LABA/ICS devices. J Allergy Clin Immunol 2004 0.79
20 PHARMAC responds on Herceptin assumptions and decisions. N Z Med J 2007 0.78
21 PHARMAC responds on long-acting inhalers for COPD. N Z Med J 2005 0.76
22 PHARMAC responds on salbutamol. N Z Med J 2005 0.76
23 PHARMAC's response on gemcitabine and transparency. N Z Med J 2005 0.75
24 PHARMAC and EpiPen for anaphylaxis. N Z Med J 2006 0.75
25 Funding a clinical trial: the perspective of a medicines funder. Pharmacoeconomics 2008 0.75
26 PHARMAC and statins--getting the best population health gains. N Z Med J 2006 0.75
27 More on PHARMAC and tobacco control in New Zealand. N Z Med J 2006 0.75
28 PHARMAC responds on treatments for pulmonary arterial hypertension. N Z Med J 2005 0.75
29 PHARMAC responds on TNF inhibitors for inflammatory arthritis. N Z Med J 2005 0.75
30 Balancing the risks and benefits of celecoxib. Am J Med 2007 0.75
31 PHARMAC and erythropoietin for cancer patients. N Z Med J 2006 0.75
32 PHARMAC responds on agents to prevent osteoporotic fractures. N Z Med J 2006 0.75
33 PHARMAC and statins--correction is needed. N Z Med J 2007 0.75
34 Specific oral contraceptive use and venous thromboembolism resulting in hospital admission. N Z Med J 2004 0.75
35 PHARMAC's updated guidelines for cost-effectiveness analyses, with new discount rate. N Z Med J 2007 0.75
36 Child abuse in Australian camps-whose business, and who should speak out? N Z Med J 2016 0.75
37 PHARMAC has no cost-effectiveness threshold. N Z Med J 2012 0.75
38 PHARMAC's updated guidelines for cost-utility analyses, with new QALYs per $1M metric. N Z Med J 2012 0.75
39 Usage and equity of access to isotretinoin in New Zealand by deprivation and ethnicity. N Z Med J 2011 0.75
40 New Zealand's emissions trading scheme and health: wasting our opportunities. N Z Med J 2008 0.75
41 PHARMAC welcomes debate. N Z Med J 2005 0.75
42 Sign On--prescribing for climate health. N Z Med J 2009 0.75